|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Genome of Artemisia annua Provides Insight into the Evolution of Asteraceae Family and Artemisinin Biosynthesis显示文摘Artemisia annua,通常已知的同样香甜的苦恼或 Qinghao,是到中国的一个灌木土著人并且长被用于药用的目的。A。annua 现在作为有势力抗疟药混合物的唯一的生来的来源全球性被栽培, artemisinin。这里,我们报导 A 的 1.74-gigabase 染色体的一个高质量的草稿集会。annua,高度异质接合,富于重复定序,并且包含 63 ? 226 编码蛋白质的基因,在定序的植物种类之中的最大的数字之一。我们发现了那,作为在 Asteraceae 的一些定序的染色体之一, A。annua 染色体包含对这大被子植物 clade 特定的很多基因。尤其是,扩大和编码涉及萜烯生合成的酶的基因的功能的多样化与 artemisinin biosynthetic 小径的进化一致。我们进一步由介绍那 A 的 transcriptome 揭示了。annua 发展了复杂 transcriptional 规章的网络位于 \O 下面 artemisinin 生合成。把转基因的 A 基于我们产生了的全面 genomic 和 transcriptomic 分析。artemisinin 高级的生产的 annua 线,它现在为大规模生产准备好了并且将从而帮助遇见增加 artemisinin 的全球需求的挑战。 | Qian Shen Lida Zhang Zhihua Liao Shengyue Wang Tingxiang Yan Pu Shi Meng Liu Xueqing Fu Qifang Pan Yuliang Wang Zongyou Lv Xu Lu Fangyuan Zhang Weimin Jiang Yanan Ma Minghui Chen Xiaolong Hao Ling Li Yueli Tang Gang Lv Yan Zhou Xiaofen Sun Peter E. Brodelius Jocelyn K.C. Rose Kexuan Tang | 2018 | Molecular Plant2018，11，6： | 47 |
| 2 | China National Medical Products Administration approval summary:anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy显示文摘Background:On May 8,2018,the China National Medical Products Administration(NMPA)approved anlotinib,an orally administered anti-angiogenesis inhibitor,for the treatment of patients with advanced non-small cell lung can-cer(NSCLC)who have progressed after treatment with two or more lines of prior systemic chemotherapy.Main body of the abstract:China NMPA reviewed and inspected a regional double-blinded,placebo-controlled,Phase III trial comparing the overall survival(OS)of NSCLC patients between the anlotinib and placebo arms.A total of 437 patients were randomized(2:1)to receive either anlotinib(n=294)or placebo(n=143)once daily on a 2-week on and 1-week off schedule.Patients with epidermal growth factor receptor(EGFR)or activating anaplastic lymphoma kinase(ALK)genomic tumor aberrations should have disease progression on NMPA-approved therapy.Anlotinib is the first NMPA-approved drug for patients with advanced NSCLC who have progressed on at least two lines of prior systemic chemotherapies in China.The approval was based on a statistically and clinically significant improvement in median OS with anlotinib(9.46 months)compared with placebo[6.37 months;hazard ratio(HR])=0.70,95%confidence interval(CI)=0.55-0.89;two-sided log-rank P=0.002].The confirmed objective response rate(ORR)was 9.2%in the anlotinib arm and 0.7%in the placebo arm.The median duration of response(DoR)was 4.83 months,with a 95%CI of 3.31-6.97 months.The toxicity profile of anlotinib was consistent with that of known anti-angiogenesis inhibitors.Common adverse drug reactions(ADRs)in anlotinib-treated patients included hypertension(67.4%),hand-foot syndrome(43.9%),hemoptysis(14.0%),thyroid stimulating hormone(TSH)elevation(46.6%),and corrected QT interval(QTc)prolongation(26.2%).Short conclusion:Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy. | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | Cancer Communications2019，39，1： | 35 |
| 3 | 中国国家药品监督管理局批准安罗替尼用于经两种系统化疗后疾病进展的晚期非小细胞肺癌的治疗显示文摘背景2018年5月8日,中国国家药品监督管理局(National Medical Products Administration,NMPA)批准了小分子多靶点抗血管抑制剂盐酸安罗替尼,用于既往经过至少两种系统化疗后疾病进展的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗。概要中国NMPA审查了一项随机双盲、安慰剂对照的III期临床试验,该临床试验的主要终点为总生存期(overall survival,OS)。试验共纳入437例患者随机分组(2∶1)接受安罗替尼(n=294)或安慰剂(n=143)治疗,每日1次,连服2周,停药1周。表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏感突变或间变性淋巴瘤激酶(activating anaplasticlymphomakinase,ALK)阳性的患者须经过NMPA已批准的药物治疗后出现疾病进展。安罗替尼为中国NMPA批准的用于治疗既往经过两种及以上系统化疗后疾病进展的晚期NSCLC患者的首个药物。安罗替尼组的中位OS(9.46个月)较安慰剂组[6.37个月;风险比(hazard ratio,HR)=0.70,95%置信区间(confidence Interval,CI):0.55–0.89;双侧log-rank P=0.002]显著延长。安罗替尼组的客观缓解率(objective responserate,ORR)为9.2%,安慰剂组为0.7%。安罗替尼组的中位缓解持续时间(durationofresponse,DoR)为4.83个月,95%CI为3.31–6.97个月。安罗替尼的常见不良反应(adverse drug reactions,ADRs)包括高血压(67.4%)、手足综合征(43.9%)、咳血(14.0%)、促甲状腺激素(thyroid stimulating hormone,TSH)升高(46.6%)、心电图QT间期(corrected QT Interval,QTc)延长(26.2%)。结论安罗替尼显著延长了患者的OS,可作为经二线及以上化疗后晚期或转移性非小细胞肺癌的一种新的治疗方案。 | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | 癌症2019，38，12： | 7 |
| 4 | Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer显示文摘Small-cell lung cancer(SCLC)is the most aggressive and lethal subtype of lung cancer,for which,better understandings of its biology are urgently needed.Single-cell sequencing technologies provide an opportunity to profile individual cells within the tumor microenvironment(TME)and investigate their roles in tumorigenic processes.Here,we performed high-precision single-cell transcriptomic analysis of~5000 individual cells from primary tumors(PTs)and matched normal adjacent tissues(NATs)from 11 SCLC patients,including one patient with both PT and relapsed tumor(RT).The comparison revealed an immunosuppressive landscape of human SCLC.Malignant cells in SCLC tumors exhibited diverse states mainly related to the cell cycle,immune,and hypoxic properties.Our data also revealed the intratumor heterogeneity(ITH)of key transcription factors(TFs)in SCLC and related gene expression patterns and functions.The non-neuroendocrine(non-NE)tumors were correlated with increased inflammatory gene signatures and immune cell infiltrates in SCLC,which contributed to better responses to immune checkpoint inhibitors.These findings indicate a significant heterogeneity of human SCLC,and intensive crosstalk between cancer cells and the TME at single-cell resolution,and thus,set the stage for a better understanding of the biology of SCLC as well as for developing new therapeutics for SCLC. | Yanhua Tian Qingqing Li Zhenlin Yang Shu Zhang Jiachen Xu Zhijie Wang Hua Bai Jianchun Duan Bo Zheng Wen Li Yueli Cui Xin Wang Rui Wan Kailun Fei Jia Zhong Shugeng Gao Jie He Carl MGay Jianjun Zhang Jie Wang Fuchou Tang | 2022 | Signal Transduction and Targeted Therapy2022，7，11： | 1 |
| 5 | Molecular insights into AabZIP1-mediated regulation on artemisinin biosynthesis and drought tolerance in Artemisia annua显示文摘Artemisia annua is the main natural source of artemisinin production.In A.annua,extended drought stress severely reduces its biomass and artemisinin production while short-term water-withholding or abscisic acid(ABA)treatment can increase artemisinin biosynthesis.ABA-responsive transcription factor AabZIP1 and JA signaling AaMYC2 have been shown in separate studies to promote artemisinin production by targeting several artemisinin biosynthesis genes.Here,we found AabZIP1 promote the expression of multiple artemisinin biosynthesis genes including AaDBR2 and AaALDH1,which AabZIP1 does not directly activate.Subsequently,it was found that AabZIP1 up-regulates AaMYC2expression through direct binding to its promoter,and that AaMYC2 binds to the promoter of AaALDH1to activate its transcription.In addition,AabZIP1 directly transactivates wax biosynthesis genes AaCER1and AaCYP86A1.The biosynthesis of artemisinin and cuticular wax and the tolerance of drought stress were significantly increased by AabZIP1 overexpression,whereas they were significantly decreased in RNAi-AabZIP1 plants.Collectively,we have uncovered the AabZIP1-AaMYC2 transcriptional module as a point of cross-talk between ABA and JA signaling in artemisinin biosynthesis,which may have general implications.We have also identified AabZIP1 as a promising candidate gene for the development of A.annua plants with high artemisinin content and drought tolerance in metabolic engineering breeding. | Guoping Shu Yueli Tang Mingyuan Yuan Ning Wei Fangyuan Zhang Chunxian Yang Xiaozhong Lan Min Chen Kexuan Tang Lien Xiang Zhihua Liao | 2022 | Acta Pharmaceutica Sinica B2022，12，3： | 1 |
| 6 | Dynamical Study of the Radiation Environment at the Interaction Region of BEPC显示文摘A method to study dynamically the radiation environment at the interaction region of the Beijing Electron-Positron Collider is described.It is shown that the radiation levels are closely correlated to the beam conditions of the collider:most radiation occurs during injection and sudden loss(or dump)of beam,while Colliding beams produce at least an order of magnitude less radiation background which decreases gradually with time.By using this method,an extra source of background for the Beijing Spectrometer experiment at the collider has been found and eliminated. | CHEN Yu GU Yifan LI Jianping TANG Yueli | 1993 | Chinese Physics Letters1993，10，5： | 0 |
| 7 | Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation显示文摘Several phosphoinositide 3-kinase(PI3 K) inhibitors are currently approved to treat hematolymphatic malignant diseases worldwide, and many drugs that have the same target are in the clinical research stage. In March 2022,duvelisib became the first PI3 K inhibitor approved in China indicated for the treatment of hematolymphatic malignant diseases. Meanwhile, linperlisib and copanlisib have almost completed the technical review of the clinical specialty. The Center for Drug Evaluation(CDE) of the China National Medical Products Administration(NMPA) found that class I PI3 K inhibitors can cause various degrees of immune-related adverse events, which are associated with action mechanisms, affecting the benefit-risk assessment of the drugs. On April 21, 2021, the United States Food and Drug Administration(FDA) convened the Oncologic Drugs Advisory Committee(ODAC)meeting to discuss the safety of PI3 K inhibitors indicated for hematolymphatic malignancies and their related risk of death. The hematological tumor group of CDE of the China NMPA summarized and combined the data on PI3 K inhibitors listed or under technical review for marketing authorization applications and found that such products may have unique efficacy and safety characteristics in Chinese patients with malignant lymphoma. | Limin Zou Yueli Qi Ling Tang Yu Du Meiyi Xiang Xiaoming Chen Jun Ma Zhimin Yang | 2022 | Chinese Journal of Cancer Research2022，34，4： | 0 |
| 8 | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China:from the perspective of clinical reviewers显示文摘1 BACKGROUND Before the State Council of the People’s Republic of China issued the“Opinions on the Reform of the Examination and Approval System of Pharmaceutical and Medical Devices”[1],several problems existed in China’s drug evaluation and approval system.The long approval time and low efficiency of new drug marketing seriously affected the enthusiasm for drug innovation.To this end,the current“Drug Registration Regulation”(DRR)[2]was initiated by the National Medical Products Administration of China and officially implemented on July 1,2020.To encourage clinical value-oriented drug innovation,four expedited drug programs were first proposed,including breakthrough therapy drugs,conditional approval,priority review,and special approval procedures.For drugs listed in the expedited programs,the drug regulatory authorities and professional technical institutions should provide policy and technical support,prioritize the allocation of communication and review resources,and thereafter shorten the review time as much as possible. | Limin Zou Yueli Qi Yongling Jiang Ling Tang Yu Du Boyuan Zhao Yanzhe Sun Meiyi Xiang Jun Ma Zhimin Yang | 2023 | Cancer Communications2023，43，2： | 0 |
| 9 | Microenvironment and related genes predict outcomes of patients with cervical cancer:evidence from TCGA and bioinformatic analysis显示文摘Cervical cancer(CESC)is one of the most common cancers and affects the female genital tract.Consistent HPV infection status has been determined to be a vital cause of tumorigenesis.HPV infection may induce changes to the immune system and limit the host’s immune response.Immunotherapy is therefore essential to improving the overall survival of both locally advanced and recurrent CESC patients.Using 304 relevant samples from TCGA,we assessed immune cell function in CESC patients to better understand the status of both tumor micro-environment cells and immune cells in CESC.Functional enrichment analysis,pathway enrichment analysis,and PPI network construction were performed to explore the differentially expressed genes(DEGs).The analysis identified 425 DEGs,which included 295 up-regulated genes and 130 down-regulated genes.We established that upregulation of CCL5 was correlated with significantly better survival,meaning that CCL5 expression could serve as a novel prognostic biomarker for CESC patients.We further focused on CCL5 as a hub gene in CESC,as it had significant correlations with increased numbers of several types of immune cells.Cell-type fractions of M1 macrophages were significantly higher in the high-immune-scores group,which was associated with better overall survival.Finally,we concluded that CCL5 is a promising prognostic biomarker for CESC,as well as a novel chemotherapeutic target. | WENXI GAO QIANQIAN MA CHENYU TANG YUELI ZHAN YINONG DUAN HUIHUA NI YUNZHAO XU | 2020 | BIOCELL2020，44，4： | 0 |
| 10 | Single-cell analysis reveals an Angpt4-initiated EPDC-EC-CM cellular coordination cascade during heart regeneration显示文摘Mammals exhibit limited heart regeneration ability,which can lead to heart failure after myocardial infarction.In contrast,zebrafish exhibit remarkable cardiac regeneration capacity.Several cell types and signaling pathways have been reported to participate in this process.However,a comprehensive analysis of how different cells and signals interact and coordinate to regulate cardiac regeneration is unavailable.We collected major cardiac cell types from zebrafish and performed high-precision single-cell transcriptome analyses during both development and post-injury regeneration.We revealed the cellular heterogeneity as well as the molecular progress of cardiomyocytes during these processes,and identified a subtype of atrial cardiomyocyte exhibiting a stem-like state which may transdifferentiate into ventricular cardiomyocytes during regeneration.Furthermore,we identified a regeneration-induced cell(RIC)population in the epicardium-derived cells(EPDC),and demonstrated Angiopoietin 4(Angpt4)as a specific regulator of heart regeneration.angpt4 expression is specifically and transiently activated in RIC,which initiates a signaling cascade from EPDC to endocardium through the Tie2-MAPK pathway,and further induces activation of cathepsin K in cardiomyocytes through RA signaling.Loss of angpt4 leads to defects in scar tissue resolution and cardiomyocyte proliferation,while overexpression of angpt4 accelerates regeneration.Furthermore,we found that ANGPT4 could enhance proliferation of neonatal rat cardiomyocytes,and promote cardiac repair in mice after myocardial infarction,indicating that the function of Angpt4 is conserved in mammals.Our study provides a mechanistic understanding of heart regeneration at single-cell precision,identifies Angpt4 as a key regulator of cardiomyocyte proliferation and regeneration,and offers a novel therapeutic target for improved recovery after human heart injuries. | Zekai Wu Yuan Shi Yueli Cui Xin Xing Liya Zhang Da Liu Yutian Zhang Ji Dong Li Jin Meijun Pang Rui-Ping Xiao Zuoyan Zhu Jing-Wei Xiong Xiangjun Tong Yan Zhang Shiqiang Wang Fuchou Tang Bo Zhang | 2023 | Protein & Cell2023，14，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员